992
Views
14
CrossRef citations to date
0
Altmetric
Research Papers

Safety and immunogenicity of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in normal rats

, , , , , , , , , , , , , & show all
Pages 2777-2783 | Received 10 Mar 2015, Accepted 13 Jul 2015, Published online: 23 Dec 2015

Figures & data

Table 1. Vaccination effect of normal rats with pcDNA-CCOL2A1 vaccine at the maximum doses of 3 mg/kg on general health status and behavior on 14 days after vaccination (n=6)Footnote

Table 2. Vaccination effect of normal rats with pcDNA-CCOL2A1 vaccine at the maximum doses of 3 mg/kg on hematological clinical rountine parameters on 2 nd week after vaccination (n = 6, x¯ ± s)

Table 3. Vaccination effect of normal rats with pcDNA-CCOL2A1 vaccine at the maximum doses of 3 mg/kg on serum biochemistry rountine parameters on 2nd week after vaccination (n = 6, x¯ ± s)

Figure 1. Histopathological analysis of various tissues from normal rats vaccinated with pcDNA-CCOL2A1 at a maximum dosage of 3 mg/kg on day 14 after a single intramuscular injection into the hind leg. H&E staining, original magnification: 200×. (A) Samples from the control rats. (B) Samples from the vaccinated normal rats. These data are representative of 3 experiments. Three separate experiments yielded similar results.

Figure 1. Histopathological analysis of various tissues from normal rats vaccinated with pcDNA-CCOL2A1 at a maximum dosage of 3 mg/kg on day 14 after a single intramuscular injection into the hind leg. H&E staining, original magnification: 200×. (A) Samples from the control rats. (B) Samples from the vaccinated normal rats. These data are representative of 3 experiments. Three separate experiments yielded similar results.

Table 4. Vaccination effect of normal rats with pcDNA-CCOL2A1 vaccine at the maximum doses of 3mg/kg on plasma production of anti-CII IgG antibodies on 2nd week after vaccination

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.